489 related articles for article (PubMed ID: 1375700)
1. In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.
Bayle C; Vitté-Mony I; Lang P; Pico J; Hercend T; Bertoglio J
Leukemia; 1992 May; 6(5):470-6. PubMed ID: 1375700
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2-, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells.
Naume B; Gately M; Espevik T
J Immunol; 1992 Apr; 148(8):2429-36. PubMed ID: 1373169
[TBL] [Abstract][Full Text] [Related]
3. Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells.
Baume DM; Robertson MJ; Levine H; Manley TJ; Schow PW; Ritz J
Eur J Immunol; 1992 Jan; 22(1):1-6. PubMed ID: 1370410
[TBL] [Abstract][Full Text] [Related]
4. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype.
Weil-Hillman G; Voss SD; Fisch P; Schell K; Hank JA; Sosman JA; Sugamura K; Sondel PM
Cancer Res; 1990 May; 50(9):2683-91. PubMed ID: 1691679
[TBL] [Abstract][Full Text] [Related]
5. Morphological, phenotypic and functional characteristics of a pure population of CD56+ CD16- CD3- large granular lymphocytes generated from human duodenal mucosa.
Pang G; Buret A; Batey RT; Chen QY; Couch L; Cripps A; Clancy R
Immunology; 1993 Jul; 79(3):498-505. PubMed ID: 7691728
[TBL] [Abstract][Full Text] [Related]
6. Different mechanisms of activation of proliferating CD3+ cells in patients with lymphoproliferative disease of granular lymphocytes.
Zambello R; Cassatella MA; Trentin L; Bulian P; Siviero F; Feruglio C; Agostini C; Vespignani M; Chisesi T; Pizzolo G
Leukemia; 1991 Nov; 5(11):942-50. PubMed ID: 1835747
[TBL] [Abstract][Full Text] [Related]
7. Accumulation of CD16-CD56+ natural killer cells with high affinity interleukin 2 receptors in human early pregnancy decidua.
Nishikawa K; Saito S; Morii T; Hamada K; Ako H; Narita N; Ichijo M; Kurahayashi M; Sugamura K
Int Immunol; 1991 Aug; 3(8):743-50. PubMed ID: 1716974
[TBL] [Abstract][Full Text] [Related]
8. The CD56 adhesion molecule is the major determinant for detecting non-major histocompatibility complex-restricted cytotoxic mononuclear cells from the intestinal lamina propria.
Van Tol EA; Verspaget HW; Peña AS; Kraemer CV; Lamers CB
Eur J Immunol; 1992 Jan; 22(1):23-9. PubMed ID: 1370415
[TBL] [Abstract][Full Text] [Related]
9. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
10. Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders.
Hoshino S; Oshimi K; Teramura M; Mizoguchi H
Blood; 1991 Dec; 78(12):3232-40. PubMed ID: 1835892
[TBL] [Abstract][Full Text] [Related]
11. Costimulatory signals are required for optimal proliferation of human natural killer cells.
Robertson MJ; Manley TJ; Donahue C; Levine H; Ritz J
J Immunol; 1993 Mar; 150(5):1705-14. PubMed ID: 7679691
[TBL] [Abstract][Full Text] [Related]
12. In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors.
Whiteside TL; Wang YL; Selker RG; Herberman RB
Cancer Res; 1988 Nov; 48(21):6069-75. PubMed ID: 2971433
[TBL] [Abstract][Full Text] [Related]
13. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients.
Fujimiya Y; Suzuki Y; Katakura R; Miyagi T; Yamaguchi T; Yoshimoto T; Ebina T
Clin Cancer Res; 1997 Apr; 3(4):633-43. PubMed ID: 9815731
[TBL] [Abstract][Full Text] [Related]
14. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens.
Weil-Hillman G; Fisch P; Prieve AF; Sosman JA; Hank JA; Sondel PM
Cancer Res; 1989 Jul; 49(13):3680-8. PubMed ID: 2471587
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
16. Analysis of lymphocyte phenotype and T cell receptor genotype in Felty's syndrome.
Meliconi R; Kingsley GH; Pitzalis C; Sakkas L; Panayi GS
J Rheumatol; 1992 Jul; 19(7):1058-64. PubMed ID: 1380988
[TBL] [Abstract][Full Text] [Related]
17. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand.
Carson WE; Fehniger TA; Caligiuri MA
Eur J Immunol; 1997 Feb; 27(2):354-60. PubMed ID: 9045904
[TBL] [Abstract][Full Text] [Related]
18. CD16- CD56+ natural killer cells after bone marrow transplantation.
Jacobs R; Stoll M; Stratmann G; Leo R; Link H; Schmidt RE
Blood; 1992 Jun; 79(12):3239-44. PubMed ID: 1375847
[TBL] [Abstract][Full Text] [Related]
19. The effect of interleukin 2 and transforming growth factor-beta 2 (TGF-beta 2) on the proliferation and natural killer activity of decidual CD16- CD56bright natural killer cells.
Saito S; Morii T; Enomoto M; Sakakura S; Nishikawa K; Narita N; Ichijo M
Cell Immunol; 1993 Dec; 152(2):605-13. PubMed ID: 7504983
[TBL] [Abstract][Full Text] [Related]
20. A novel functional cell surface dimer (Kp43) expressed by natural killer cells and T cell receptor-gamma/delta+ T lymphocytes. I. Inhibition of the IL-2-dependent proliferation by anti-Kp43 monoclonal antibody.
Aramburu J; Balboa MA; Ramírez A; Silva A; Acevedo A; Sánchez-Madrid F; De Landázuri MO; López-Botet M
J Immunol; 1990 Apr; 144(8):3238-47. PubMed ID: 1691231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
